Direct-acting antiviral medications for chronic hepatitis C virus infection.


Journal Article

Treatment of hepatitis C virus has traditionally been difficult because of low rates of treatment success and high rates of treatment discontinuation due to side effects. Current standard therapy consists of pegylated interferon α and ribavirin, both of which have nonspecific and largely unknown mechanisms of action. New therapies are in development that act directly on the hepatitis C virus at various points in the viral life cycle. Published clinical trial data on these therapies are summarized in this paper. A new era of hepatitis C virus treatment is beginning, the ultimate goals of which will be directly targeting the virus, shortening the length of therapy, improving sustained virologic response rates, and minimizing side effects.

Full Text

Duke Authors

Cited Authors

  • Jazwinski, AB; Muir, AJ

Published Date

  • March 2011

Published In

Volume / Issue

  • 7 / 3

Start / End Page

  • 154 - 162

PubMed ID

  • 21528041

Pubmed Central ID

  • 21528041

International Standard Serial Number (ISSN)

  • 1554-7914


  • eng

Conference Location

  • United States